Post by Algaurizin

Launching a drug isn’t a rocket launch, it’s a campfire and a beachhead. New issue of Pipeline to Market explores why up to 70% of launches underperform and how commercial execution, payer alignment, physician education, patient support, supply readiness, and localization, often determines whether great science reaches patients. Key ideas in this issue: “Antagonistic timing”: approval arrives before the system is ready. Campfire launch vs. Rocket launch: phased rollout, continuous learning, long-term adoption. Beachhead strategy: start small (academic centers, regions) to build real-world evidence. Localization trap: global plans that ignore local systems and culture block access. Early warning signs: low salesforce confidence, inconsistent messaging, growing prior‑auth friction. Case studies I highlight: Orforglipron, Mezigdomide, KarXT, each shows disciplined, phased commercialization in practice. Why this matters to clinicians: commercial strategy shapes access, reimbursement, education, and adherence, and ultimately whether patients can get the treatments they need. Read Issue #43 of Pipeline to Market to dive deeper. Then tell me, what’s the biggest barrier you’ve seen after a new therapy launch: payer access, clinician education, patient support, supply, or something else? Share your experience below.